Peanut Allergen Inhibitor Developed Using Nanoparticles

GEN | April 09, 2019

Preventing the torrent of signaling molecules that are released during an adverse peanut reaction could not only prove to be helpful to many of the estimated 4.2 million children living with this allergy, but it could also be life-saving to those individuals where the slightest trace of peanut or peanut ingredients could have fatal consequences. The allergy is the result of allergens binding with an antibody called immunoglobulin E (IgE) on the surface of immune cells, setting off a complex chain reaction that could lead to a response ranging in severity from a rash to anaphylactic shock. Now, investigators from the University of Notre Dame have effectively prevented the binding of peanut allergens with IgE to suppress the allergic reaction to peanuts using the first-in-class design of allergen-specific inhibitors. Findings from the study were published today in PNASthrough an article titled “Designer covalent heterobivalent inhibitors prevent IgE-dependent responses to peanut allergen.”

Spotlight

Biotechnology has the power to increase human health, environmental sustainability and the wellbeing of consumers and farm communities globally. For example, higher yielding crops developed through agricultural biotechnology can contribute toward meeting the United Nation’s estimated need for a 50 percent increase in world food production by 2030.

Spotlight

Biotechnology has the power to increase human health, environmental sustainability and the wellbeing of consumers and farm communities globally. For example, higher yielding crops developed through agricultural biotechnology can contribute toward meeting the United Nation’s estimated need for a 50 percent increase in world food production by 2030.

Related News

CELL AND GENE THERAPY

Cellares and Poseida Therapeutics Join Forces to Speed Up Cell Therapy Manufacturing

Cellares Corporation | July 16, 2021

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Center as the third entity to join Cellares' EAPP. Cellares launched the EAPP in 2020 to provide participants awareness and early access to Cellares' Cell Shuttle, a next-generation cell therapy manufacturing platform that enables closed, automated, and scalable cell therapy production. Poseida's involvement in the initiative adds to the Cell Shuttle's development, range of usage, and applicability by providing insight and experience in manufacturing processes for various autologous and allogeneic cell therapies. Poseida is presently testing two autologous CAR-T product candidates in the clinic: P-BCMA-101 for relapsed/refractory multiple myeloma and P-PSMA-101 for metastatic castrate-resistant prostate cancer. The firm, which completed an initial public offering in July 2020, is also developing off-the-shelf versions of these treatments and TCR-T, anti-c-kit CAR-T, induced pluripotent stem cells (iPSCs), genetically modified hematopoietic stem cells (HSCs), and NK cells. In addition, Carl June, M.D., an immunotherapy pioneer and renowned oncologist who advised Cellares on creating the Cell Shuttle has just joined Poseida's Immuno-Oncology Scientific Advisory Board. Poseida will assess the Cell Shuttle prototypes and give statistics and written comments related to their function and performance as part of Cellares' EAPP. In addition, user studies will be conducted to assess the Cell Shuttle's hardware and software, product requirements, release criteria, and process processes to ensure product-market fit. About The Cell Shuttle The Cell Shuttle is a flexible and scalable automated and closed end-to-end production solution that allows clients to execute the precise procedures required for their cell therapy. Compared to presently existing cell therapy manufacturing methods, this next-generation platform allows for a threefold decrease in process failure rates and the ability to produce 10+ patient doses in parallel, improving manufacturing scalability by order of magnitude. For most processes, this will reduce per-patient manufacturing costs by up to 70%. About Cellares Corporation Cellares is rethinking cell therapy manufacturing and accelerating access to life-saving cell therapies. The business is working on a one-of-a-kind approach to solving the difficulties of generating cell therapies that are cheaper and broadly accessible to people in need. Cellares' proprietary platform, the Cell Shuttle, eliminates the need for biopharma companies, academic research centers, and CDMOs to choose between a manufacturing platform that is semi-automated but lacks workflow flexibility or one that provides customization but lacks the end-to-end automation required to manufacture at scale. The business is based in South San Francisco, California.

Read More

Cedilla Therapeutics Completes $82.6M Series B Financing

Cedilla Therapeutics | October 25, 2021

Cedilla Therapeutics a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 million. The oversubscribed Series B expansion includes new investors RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital, along with participation from existing investor Third Rock Ventures.“We are grateful for the support from our new and existing investors, which reflects the promise of our novel approach to conditionally modulating proteins as well as the unique potential of our lead programs, inhibitors against TEAD and CDK2, two critical but historically undruggable targets,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “With this financing, we plan to accelerate and expand our development efforts by progressing our most advanced programs toward the clinic while continuing to invest in ongoing discovery efforts against additional high value cancer targets.” Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach and esophageal cancers. The company plans to initiate investigational new drug application-enabling studies for the TEAD program in the first half of 2022 and for the CDK2 program in the second half of 2022. In conjunction with the financing, Jake Simson, Ph.D., Partner at RA Capital Management, joins Cedilla’s Board of Directors. Dr. Glucksmann continued, “We are pleased to welcome Jake to our Board of Directors. He brings a wealth of experience advising companies from the earliest stages of company formation through their maturation into fully integrated biopharmaceutical organizations. We look forward to his many contributions as we continue to grow Cedilla into a clinical-stage organization with a robust and growing portfolio of product candidates.” “Cedilla brings a new dimension to precision oncology by conditionally modulating proteins in their functional state Preclinical data generated to-date suggest that Cedilla’s lead programs may challenge historical perceptions of TEAD and CDK2 as undruggable targets and could offer patients new options that would be well-tolerated and extremely effective. In addition, Cedilla’s approach, based on a deep understanding of how the cellular context modulates protein activity, could deliver superior inhibitors against a range of other key cancer drivers. I look forward to partnering with the team with the aim to deliver a broad portfolio of small molecule medicines, each with potential profound benefit to patients.” Jake Simson, Ph.D., Partner at RA Capital Management About Cedilla Therapeutics Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. x

Read More

INDUSTRIAL IMPACT

Novo Holdings Leads US$21M Series A Financing in BIOMILQ

Novo Holdings | October 21, 2021

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estimated that 75%1 of women are unable to exclusively breastfeed for the six months after birth as recommended by the American Academy of Pediatrics and the World Health Organization. Breastfeeding can be difficult due to latching issues, birth complications, discomfort or pain, exhaustion, inadequate milk supply, amongst other reasons. Alternative supplements, such as bovine-based infant formula, can lack the nutritional and bioactive composition found in breast milk. BIOMILQ's technology and solutions can be transformative in the field of infant nutrition, a market with a significant need for innovation. "Our mission is to make a growing and positive impact on health, science and society. We are delighted to support BIOMILQ through its journey pioneering mammary biotechnology. Its products have the potential to disrupt the infant supplemental feeding industry. We aim to use our scientific knowledge, operational expertise and global network to further strengthen the Company's ability to improve lives. Kartik Dharmadhikari, Partner at Novo Groand BIOMILQ Board Director Michelle Egger, Chief Executive Officer and Co Founder of BIOMILQ, added: "We are very pleased to have such experienced investors in our Series A financing. Novo Holdings, as a leading international life science investor, lends significant market experience and technical knowhow to BIOMILQ's mission to nourish healthier infants, empower parents through choice, and contribute to a healthier planet. The investor syndicate was led by Novo Holdings, with participation from Breakthrough Energy Ventures, Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund and Gaingels. About Novo Holdings A/S Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information. About BIOMILQ BIOMILQ's mission is to close the nutritional gap between infant feeding options. In June 2021, BIOMILQ announced its capability of producing a milk product, derived from human mammary cells, that has macronutrient profiles that closely match the expected types and proportions of proteins, complex carbohydrates, fatty acids and other bioactive lipids that are known to be abundantly present in breastmilk. 1 "Breastfeeding Among U.S. Children Born 2011–2018, CDC National Immunization Survey." Centers for Disease Control

Read More